Associations Between Intravenous Iron, Inflammation and FGF23 in Non-Dialysis Patients with Chronic Kidney Disease Stages 3-5
Open Access
- 8 February 2018
- journal article
- research article
- Published by S. Karger AG in Kidney and Blood Pressure Research
- Vol. 43 (1) , 143-151
Abstract
Background/Aims: Both iron deficiency and chronic inflammation are highly prevalent in patients with chronic kidney disease (CKD). The effect of intravenous iron infusion on mineral metabolism in CKD may be modified by inflammation. Intravenous iron theraphy may reduce peripheral degradation, secretion, clearence of iFGF23 and lead to hypophosphatemia. The aim of the study was to evaluate the effect of intravenous iron on mineral metabolism in CKD patients. Methods: 35 non-dialysis patients with CKD stages 3-5. received 100 mg/24h of ferric oxide saccharated solution for 5 days. Serum calcium (Ca), phosphorus (P), parathormone (PTH), intact-FGF23 (iFGF23), C-terminal-FGF23 (cFGF23), bone alkaline phosphatase (BAP) and high-sensitive CRP were assessed on day 1 and 3 at baseline and 2 hours after each dose administration and once on day 6. Plasma iFGF23 and cFGF23, as well as serum BAP were measured with ELISA and other parameters with standard automated laboratory methods. Results: Serum iFGF23 increased after iv iron on day 1 and 6 (from 268.9±446.5 to 326.3±529.9 on day 1; p=0.05 and to 451.4±601 pg/mL on day 6; p=0.03). cFGF23 was reduced only on day 1 (from 654.3±441.3 to 473.6±414 RU/mL; p=0.016). P concentration decreased significantly two hours after the first iron infusion (from 1.69±0.5 to 1.54±0.35 mmol/l; p=0.003). In following days the changes of cFGF23, P and of other calcium-phosphate metabolism were not significant. Serum CRP correlated neither with iFGF-23 nor cFGF-23. Conclusion: Intravenous iron supplementation may only transiently affect the production and degradation of FGF23 resulting in hypophosphatemia at the commencement of iron therapy. Chronic low-grade inflammation does not seem to play a role in that mechanism.Keywords
This publication has 35 references indexed in Scilit:
- Effect of ferric carboxymaltose on serum phosphate and C-terminal FGF23 levels in non-dialysis chronic kidney disease patients: post-hoc analysis of a prospective studyBMC Nephrology, 2013
- Iron Sucrose Impairs Phagocytic Function and Promotes Apoptosis in Polymorphonuclear LeukocytesAmerican Journal of Nephrology, 2012
- Phosphate homeostasis and its role in bone healthPediatric Nephrology, 2012
- Approach to the Hypophosphatemic PatientThe Journal of Clinical Endocrinology & Metabolism, 2012
- Low Molecular Weight Iron Dextran Increases Fibroblast Growth Factor‐23 Concentration, Together With Parathyroid Hormone Decrease in Hemodialyzed PatientsTherapeutic Apheresis and Dialysis, 2012
- Regulation and Function of the FGF23/Klotho Endocrine PathwaysPhysiological Reviews, 2012
- Effect of Intravenous Saccharated Ferric Oxide on Serum FGF23 and Mineral Metabolism in Hemodialysis PatientsAmerican Journal of Nephrology, 2011
- When is high-dose intravenous iron repletion needed? Assessing new treatment optionsDrug Design, Development and Therapy, 2011
- FGF23 Elevation and Hypophosphatemia after Intravenous Iron Polymaltose: A Prospective StudyThe Journal of Clinical Endocrinology & Metabolism, 2009
- Phosphatonins and the Regulation of Phosphate HomeostasisAnnual Review of Physiology, 2007